Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml. The study aimed at reducing NT-proBNP from baseline at 12 weeks. Results were positive; reduced left atrial size and an improvement in NYHA class were also observed. The drug was well tolerated and had less adverse effects than the comparator valsartan.
Scott Solomon
2012-08-25
Original title: Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Patients with Heart Failure and Preserved Ejection Fraction: Primary Results from the PARAMOUNT Study
